February 19, 2021
According to a recent study titled ‘U.S. Non-Invasive Prenatal Testing Market - Growth, Demand, Trends, Opportunity, Forecasts (2020 - 2027)’, available with Market Study Report LLC, U.S. non-invasive prenatal testing market is projected to register a year-over-year growth rate of 18% over 2020-2027, subsequently accounting USD 2.2 billion by the end of the stipulated timeframe.
As per the findings of the report, growing risk of chromosomal abnormalities with increasing maternal age, escalating cases of chromosomal aneuploidies among fetus, and technological advancements in product development are fueling U.S. non-invasive prenatal testing market growth.
Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2915595/
Moreover, rising awareness regarding non-invasive prenatal testing, shifting preferences towards non-invasive techniques, recommendation to utilize NIPT as per American College of Obstetricians and Gynecologists (ACOG) guidelines, and growing focus towards improving reimbursement scenario are the other factors contributing the industry expansion.
Proceeding further, restraints, limitations, and challenges in U.S. non-invasive prenatal testing market sphere are expounded. The research literature attempts to provide a holistic understanding of the industry trajectory over 2020-2027 by leveraging data from the past and current business environment.
It also makes inclusion of detailed insights on comparative test analysis by companies, covering aspects like technology, starting week, fetal fraction, twin, gender, sex chromosome aneuploidy, deletion/duplication, triploidy, turnaround time, monox accuracy, egg donor, and many more.
Additionally, this report has been revised to incorporate the latest updates on the reimbursement patterns and regulatory framework of the United States non-invasive prenatal testing market.
The research also compiles data on competitive developments, including mergers & acquisitions, collaboration deals, Venture Capital Investment distribution, partnerships deals, and exclusive and licensing agreement.
Leading players in U.S. non-invasive prenatal testing industry sphere are Integrated Genetics (LabCorp), Ariosa Diagnostics (acquired by Roche), Agilent Technologies, Inc., Invitae Corp., Yourgene Health plc, PerkinElmer, Inc., Progenity, Inc., GenPath (ioReference Laboratories, Inc.), Centogene N.V., Myriad Genetics, Inc., Quest Diagnostics, Natera, Inc., and Illumina, Inc.